"There's Nothing Like Helping Patients," Susan Molineaux, Calithera

Podcast Sponsor: Addgene - Today’s Podcast is sponsored by Addgene, a non-profit organization facilitating biomedical research by operating a library for published and useful plasmids. Find out more at www.addgene.org


Susan Molineaux, CEO, Calithera Bio and Contact Info

Chapters: (Advance the marker)

1:17 Is Calithera the ideal model for drug discovery and development?

2:09 With virtual model, "scientists have no skin in the game"

12:29 $40 million the right number

14:38 Success at Proteolix - "there's nothing like helping patients"

19:45 What is "negative persistence?"

23:27 "I grew up thinking math and science were great. There was no gender barrier."

29:16 "I didn't raise my hand and say I just need to manage."

33:40 When did you say I'm going to found a biotech company?

38:39 Why is mentorship important?

41:40 Thoughts on Affordable Care Act

Susan Molineaux thrives on the knowledge that what she does each day is making a difference in the lives of patients. CEO and founder of Calithera BioSciences, a start-up biotech housed in the same building with Crescendo Biosciences in South San Francisco, Molineaux knows the taste of success. Previously she led Proteolix in the development of cafilzomib, a therapeutic for multiple myeloma patients. Proteolix was bought out by Onyx Pharmaceuticals during late stage trials for a hefty sum. The purchase is paying off for Onyx as they just received FDA approval for the drug and saw their stock take a big jump.

Susan says her success comes from an early grounding in science that was free from gender barriers. She's a speaker at many conferences around the Bay Area and mentors for local entrepreneurs and students. Susan talks about what she's doing at Calithera and weighs in on what could be a better model for drug development.

Academia.edu and the Evolution of Peer Review with Richard Price

Podcast brought to you by: Assay Depot - the world's largest cloud-based marketplace for research services. With Assay Depot, you can easily find the perfect research service provider and manage your project from anywhere in the world.


Richard Price, Academia.edu Bio and Contact Info

Chapters (Move marker to advance)

0:50 Connections between entrepreneurship and philosophy

6:19 How did you get a ".edu" address?

10:04 Difference from other platforms (Mendeley, Google Scholar)

14:37 Peer review is evolving

24:17 What are the privacy challenges for the new model?

26:42 Site numbers

28:42 Can research truly be sped up?

33:34 What's your ultimate goal for the site?

38:46 How do you monetize scientific content?

43:47 What is the role of philosophy in our age of science?

When one thinks of philosophers from Oxford, one thinks of John Locke tucked away in a picturesque garden writing and thinking away. Or, from the last century, such folks as Isaiah Berlin or Sir Bernard Williams. Richard Price offers a new image. A Ph D and Prize Fellow at All Souls College, Richard wrote his thesis on the philosophy of perception and how to draw the line between visible and non-visible properties. Then he went into business, moved to San Francisco, and raised millions of dollars for an online gig. If you'd like to read his thesis you can easily do so by logging on to Academia.edu, a site for sharing research that he founded.

Price says the site accelerates academic research by allowing academics (and non-academic researchers) to share their work, even before it's published in a standard journal. We talk to Richard about the features of the site and what makes it different from some of the other sharing platforms such as Mendeley and Google Scholar. Richard also shares how he became a businessman, saying that "there are connections between entrepreneurship and philosophy." One of my favorite questions of late has been what role philosophers play in our present age of science. With an open style and a pleasant agreeableness, Price is happy to speak up for his fellow philosophers.

In the Shoes of the Biotech CEO

To raise awareness of and preview the upcoming sessions at the BioExec Institute, Prescience (with UC Berkeley and Deloitte as partners) has been putting on some terrific discussion nights with thought leaders of the biopharma industry. Last night, at one of their typical hip venues in San Francisco, they hosted a panel discussion titled The Corner Office, What Is It Really Like to Be a Biotech CEO? Leading the discussion was Jim Schaeffer from Merck.

Leading Through Creative Investment: Corey Goodman, VenBio

Podcast brought to you by: Assay Depot - the world's largest cloud-based Research Exchange for pharmaceutical research services.

1:53 A new model of investing at VenBio

10:13 All the leaders of big pharma know the industry is in crisis

14:54 Attempt to change Pfizer

24:10 What excites you about the industry?

26:52 Influenced by Buddhism

32:13 City kid on a ranch

Dr. Corey Goodman is a man of many talents with an illustrious background in bio. He’s a renowned scientist, entrepreneur, educator, and corporate executive. And now his latest role is that of investor as a Partner in the VC firm, VenBio. He has been President of Pfizer’s Biotherapeutics and Bioinnovation Center, was co-founder of Exelixis and Renovis, and was a professor at Stanford Univeristy and UC Berkeley for over two decades. He’s currently an adjuct professor at UC San Francisco. Corey talks about the new model of investing he's pursuing with VenBio. He gives insight into his brief stint at Pfizer where he fostered an impressive ambition to change from the inside the world's largest drug maker. Beginning with the goal of creating a Pfizer Genentech, Corey left the pharma giant after just two years without being able to do much change at all. Corey works part of the week from his ranch, where the interview is taped, and shares some of his personal thoughts on the industry and on life. He also shares some of his music.

RS Sequencer with Hugh Martin, PacBio

Podcast Sponsor: Singulex- Watch our cardiovascular monitoring programs explained on YouTube


Hugh Martin, former CEO, Pacific Biosciences Bio and Contact Info

Listen (1:45) Key events for 2011

Listen (9:05) RS Sequencer and its advantages

Listen (9:04) Disadvantages

Listen (:54) What happened to the stock?

Listen (2:30) Mike Hunkapiller joins team

Listen (6:16) What makes a good CEO?

Listen (2:17) How do you keep good people?

Listen (5:54) Fighting cancer personally

Listen (2:42) Clinical sequencing

Listen (3:50) Company direction

Listen (3:27) CSO Eric Schadt moves to NY

As part of our series, Sequencing and Genomic Medicine, I interviewed Hugh Martin of PacBio at the end of 2011. Personally, Hugh made headlines in 09 when he went public with his diagnosis of multiple myeloma. Previously, he served as CEO of ONI Systems—a high-speed optical telecommunications company he founded in 1998 and took public in 2000 and sold to Ciena in 2002 for $1 billion. Mr Martin led PacBio through an IPO and the commercial launch of their much anticipated RS Sequencer. On Jan 6 of 2012 it was announced that Mike Hunkapiller would step in as the new CEO. We hope to bring Mike to the program soon.

George Church Talks Personalized Medicine and Synthetic Biology

This podcast originally aired on May 25th, 2011

Sponsored by: BioConference Live

Guest: Church George, PhD, Professor of Genetics, Harvard Medical School and Professor of Health Sciences & Technology, Harvard and MIT. Bio and Contact Info

Part I-Personalized MedicineChurch George Listen (20:24)

Part II-Synthetic BiologyChurch George Listen (19:04)

Part III-Personal AnecdotesChurch George Listen (06:54)

Our guest for the hour is Dr. George Church from Harvard. Dr. Church’s accomplishments are legendary among scientists in his field and beyond. His Ph.D. from Harvard in biochemistry and molecular biology with Wally Gilbert included the first direct genomic sequencing method in 1984. In 1994, the technology transfer of automated sequencing and software to Genome Therapeutics Corp. resulted in the first commercial genome sequence (the human pathogen, H. pylori). He was then involved in initiating the Human Genome Project as a Research Scientist at Biogen Inc. In 2006 he initiated the Personal Genome Project with the aim of advancing the field of Personalized Medicine. He invented the broadly-applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. He has served in advisory roles for 12 journals and 5 granting agencies and also been involved in 22 private companies including LS9-which focuses on bio-petroleum, and Knome who provides full human genome sequencing. Current research focuses on integrating biosystems-modeling with personal genomics and synthetic biology.